Glucagon-like Peptide-1 analogues and delipidation of coronary atheroma in statin-treated type 2 diabetic patients with coronary artery disease: The prespecified sub-analysis of the OPTIMAL randomized clinical trial

[1]  F. Otsuka,et al.  The effect of continuous glucose monitoring-guided glycemic control on progression of coronary atherosclerosis in type 2 diabetic patients with coronary artery disease: The OPTIMAL randomized clinical trial. , 2023, Journal of diabetes and its complications.

[2]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[3]  H. Kitahara,et al.  Relation of glucose variability to vulnerable plaque formation in patients with coronary artery disease , 2022, Heart and Vessels.

[4]  T. Hansen,et al.  Effect of liraglutide on expression of inflammatory genes in type 2 diabetes , 2021, Scientific Reports.

[5]  F. Otsuka,et al.  The association between the extent of lipidic burden and delta-fractional flow reserve: analysis from coronary physiological and near-infrared spectroscopic measures. , 2021, Cardiovascular diagnosis and therapy.

[6]  F. Otsuka,et al.  The feasibility and limitation of coronary computed tomographic angiography imaging to identify coronary lipid-rich atheroma in vivo: Findings from near-infrared spectroscopy analysis. , 2021, Atherosclerosis.

[7]  K. Duffin,et al.  Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes , 2020, The Journal of clinical endocrinology and metabolism.

[8]  M. Vaduganathan,et al.  Use of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Cardiovascular Disease: A Review. , 2020, JAMA cardiology.

[9]  P. K. Sharma.  Atherosclerosis. , 2020, The Journal of the Association of Physicians of India.

[10]  C. Mathieu,et al.  2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2019, Diabetes Care.

[11]  K. Hosoda,et al.  The efficacy of glycemic control with continuous glucose monitoring on atheroma progression: rationale and design of the Observation of Coronary Atheroma Progression under Continuous Glucose Monitoring Guidance in Patients with Type 2 Diabetes Mellitus (OPTIMAL). , 2019, Cardiovascular diagnosis and therapy.

[12]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[13]  Jie Sun,et al.  Liraglutide suppresses TNF-α-induced degradation of extracellular matrix in human chondrocytes: a therapeutic implication in osteoarthritis. , 2019, American journal of translational research.

[14]  Jinghua Liu,et al.  Association Between Blood Glucose Variability and the Characteristics of Vulnerable Plaque in Elderly Non-ST Segment Elevation Acute Coronary Syndrome Patients. , 2019, International heart journal.

[15]  C. Janovsky,et al.  Triglycerides and triglyceride-rich lipoproteins in the development and progression of atherosclerosis , 2019, Current opinion in endocrinology, diabetes, and obesity.

[16]  J. Hecksher-Sørensen,et al.  The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways , 2018, JACC. Basic to translational science.

[17]  A. Hirayama,et al.  Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study. , 2018, Atherosclerosis.

[18]  D. Drucker.  Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. , 2018, Cell metabolism.

[19]  Eyal Dassau,et al.  International Consensus on Use of Continuous Glucose Monitoring , 2017, Diabetes Care.

[20]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[21]  S. Martínez-Hervás,et al.  The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype , 2017, Diabetologia.

[22]  H. Sugihara,et al.  Effect of Glycemic Control on Chylomicron Metabolism and Correlation between Postprandial Metabolism of Plasma Glucose and Chylomicron in Patients with Type 2 Diabetes Treated with Basal-bolus Insulin Therapy with or without Vildagliptin , 2017, Journal of atherosclerosis and thrombosis.

[23]  W. Koenig,et al.  Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. , 2016, JAMA.

[24]  M. Shao,et al.  Non-HDL Cholesterol and Triglycerides: Implications for Coronary Atheroma Progression and Clinical Events , 2016, Arteriosclerosis, thrombosis, and vascular biology.

[25]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[26]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[27]  Songtao Tang,et al.  Effects of glucagon-like peptide-1 on advanced glycation endproduct-induced aortic endothelial dysfunction in streptozotocin-induced diabetic rats: possible roles of Rho kinase- and AMP kinase-mediated nuclear factor κB signaling pathways , 2016, Endocrine.

[28]  P. Fitzgerald,et al.  Association between blood glucose variability and coronary plaque instability in patients with acute coronary syndromes , 2015, Cardiovascular Diabetology.

[29]  M. Nieuwdorp,et al.  GLP1, an Important Regulator of Intestinal Lipid Metabolism. , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[30]  L. Lynch,et al.  Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus , 2014, Diabetologia.

[31]  B. Nordestgaard,et al.  Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation , 2013, Circulation.

[32]  Samin K. Sharma,et al.  Changes in plaque lipid content after short-term intensive versus standard statin therapy: the YELLOW trial (reduction in yellow plaque by aggressive lipid-lowering therapy). , 2013, Journal of the American College of Cardiology.

[33]  B. Nordestgaard,et al.  Remnant cholesterol as a causal risk factor for ischemic heart disease. , 2013, Journal of the American College of Cardiology.

[34]  R. Yeh,et al.  Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. , 2012, JACC. Cardiovascular interventions.

[35]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[36]  R. Kawamori,et al.  Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4 , 2010, Diabetes.

[37]  R. Testa,et al.  Oscillating Glucose Is More Deleterious to Endothelial Function and Oxidative Stress Than Mean Glucose in Normal and Type 2 Diabetic Patients , 2008, Diabetes.

[38]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[39]  Y. Naito,et al.  Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. , 2007, Atherosclerosis.

[40]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[41]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[42]  R. Marfella,et al.  Inflammatory Cytokine Concentrations Are Acutely Increased by Hyperglycemia in Humans: Role of Oxidative Stress , 2002, Circulation.

[43]  Peter Libby,et al.  Atherosclerosis: the new view. , 2002, Scientific American.

[44]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. , 2019, Lancet.

[45]  Arteriosclerosis, Thrombosis, and Vascular Biology Endothelial GLP-1 (Glucagon-Like Peptide-1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension , 2022 .